Clinical Trial

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Study acronym: TMF-Allo
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-06-15; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2023-02-28
Trial Details
NCT Number NCT04935684
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Ministry of Health, France, French Society of Hematology
Conditions Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia
Enrollment 150 participants
Start Date 2022-12-20
Primary Completion 2030-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-09